Science Advisory Board
< Prev — Board of directors Our management — Next >
Xandra O. Breakefield, PhD
Dr. Xandra Breakefield is a geneticist at the Center for Molecular Imaging Research and at the Molecular Neurogenetics Unit, Neuroscience Center, Massachusetts General Hospital, and is a professor of neurology in the Neuroscience Program, Harvard Medical School. The Breakefield Laboratory uses molecular genetic techniques to elucidate the etiology of inherited neurologic diseases and to develop vectors which can deliver genes to the nervous system.
Dennis Brown, PhD
Dr. Dennis Brown is Assistant Chief for Research Affairs, Director of the Program in Membrane Biology and Professor of Medicine at Massachusetts General Hospital. Dr. Brown's laboratory (Program in Membrane Biology, PMB) at the Center for Systems Biology investigates how membrane transport vesicles interact with accessory proteins and with the cytoskeleton to modulate cell function via various membrane transport proteins in physiological and pathophysiological conditions. The aim of the research is to understand how physiologically-relevant processes of fluid and electrolyte transport across epithelia are regulated at the cell and molecular levels in kidney, the male reproductive tract and other organ systems.
Raphael Bueno, MD
Dr. Raphael Bueno is a Professor of Surgery at Harvard Medical School and Associate Chief of Thoracic Surgery, Director of the Thoracic Intermediate Care Unit, the Thoracic Surgery Training Program, and the Photodynamic Therapy Program at Brigham and Women's Hospital, where he joined the Division of Surgery in 1996. His clinical interests include tracheal surgery, lung cancer, mesothelioma, esophageal cancer, benign esophageal disorders, thymomas, and minimally invasive surgery. His research interest is in genomic research in thoracic cancers, primarily to better characterize the behavior of lung cancers and mesothelioma at the molecular level and to use this knowledge to design novel diagnostic and therapeutic modalities. Dr. Bueno is a member of notable thoracic surgery professional organizations and serves on the Editorial Board of the Journal of Thoracic and Cardiovascular Surgery (JTCVS).
Bob S. Carter, MD, PhD
Dr. Bob Carter is Professor of Neurosurgery and Chief of Neurosurgery at University of California, San Diego (UCSD) Medical Center and co-leads the clinical brain tumor program at UCSD, bringing together over 50 faculty and staff focusing on brain tumor clinical care, research, and education. Dr. Carter is active in national and international neurosurgery organizations, including serving as Editor of Neurosurgery. Dr. Carter specializes in the treatment of brain tumors and complex intracranial surgery and his research involves outcomes improvement for intracranial surgery, serum biomarkers for brain tumors and development of gene transfer delivery techniques for the central nervous system.
Carlos Cordon-Cardo, MD, PhD
Dr. Carlos Cordon-Cardo is Vice Chairman of Pathology, Professor of Pathology and Urology, and Associate Director for Infrastructure at the Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center. To understand what causes variation in cancers as a means to provide better diagnoses, prognoses, and treatment for patients has been Dr. Cordon-Cardo's professional quest for the past 30 years as a research pathologist and cancer biologist. Dr. Cordon-Cardo has received a number of awards, including Membership on the "Roll of Honour" of the International Union Against Cancer (since 1996). Based on his scientific contributions, Dr. Cordon-Cardo has received numerous patents, and he has mentored over 70 investigators.
Keith T. Flaherty, MD
Dr. Keith Flaherty is a Lecturer in the Department of Medicine, Harvard Medical School, and is Director of Developmental Therapeutics, Cancer Center, Massachusetts General Hospital. At the Dana-Farber/Harvard Cencer Center, he is involved in research programs in Cutaneous Oncology and Melanoma and in Translational Pharmacology and Early Therapeutic Trials. Dr. Flaherty's research focuses on novel, molecularly targeted therapies in cancer. In this context he focused on the development of response and predictive biomarkers to define the mechanisms of action and resistance of novel therapies, as well as to identify the optimal target population.
Michael J. Manyak, MD, FACS
Dr. Michael J. Manyak is Executive Director of Global Medical Affairs for Urology Franchise at GSK and Professor of Urology, Engineering, Microbiology, and Tropical Medicine at The George Washington University (GWU). He has served as board member, consultant, or director to more than 25 biotech and pharmaceutical firms. He is a founder of Metastatin Pharmaceuticals, purchased by Samaritan Pharmaceuticals. Dr. Manyak has been granted 11 patents and has several pending. He served on the Imaging Subcommittee of the Medicare Coverage Advisory Committee for the Center for Medicare and Medicaid Services (CMS). He received a presidential appointment to the National Kidney and Urological Disease Advisory Board. He has served twice as a voting member of the FDA Regulatory Panel for Genitourinary and Gastrointestinal Devices. Dr. Manyak served as Chairman of the AUA Technology Assessment Council and on five other AUA committees related to technology. He has published nearly 200 professional abstracts, book chapters, and refereed journal articles.
John Quackenbush, PhD
Dr. John Quackenbush is Professor of Computational Biology and Bioinformatics at the Department of Biostatistics, Dana-Farber Cancer Institute, Harvard School of Public Health. Dr. Quackenbush' research group focuses on methods spanning the laboratory to the laptop that are designed to use genomic and computational approaches to reveal the underlying biology. Particular focus is on patterns of gene expression in cancer with the goal of elucidating the networks and pathways that are fundamental in the development and progression of the disease. In 2009 Dr. Quackenbush launched the Center for Cancer Computational Biology (CCCB), a Dana-Farber Strategic Plan Center focused on providing computational support more broadly to the DFCI research community.
Howard R. Soule, PhD
Howard R. Soule, PhD, coordinates global academic, government and biopharmaceutical sector research activity and is responsible for the implementation of PCF's global research strategies. From 1997 to 2004, he was Executive Vice President and Chief Science Officer of PCF. He is also a member of the Department of Defense Prostate Cancer Research Program Integration Panel. Most recently, he was Managing Director of Knowledge Universe Health and Wellness Group, a private investment firm focused on companies in the general areas of disease prevention and treatment. Dr. Soule has been with the Foundation for 11 years. Prior to joining PCF in 1997, Dr. Soule was a senior R&D executive for nine years at Corvas International, Inc., a public biotechnology company. Dr. Soule received a PhD from Baylor College of Medicine in Virology and Epidemiology and was a Post Doctoral Fellow in Immunology and Vascular Biology at the Scripps Research Institute.
Dennis Steindler, PhD
Dr. Steindler has been studying the growth and transplantation of normal brain and cancerous stem cells for over 25 years. He is also responsible for reviewing manuscripts and grants for a variety of journals and funding agencies, including formerly chairing a brain repair and stem cell-related review panel at the National Institute of Neurological Diseases and Stroke in the National Institutes of Health. His papers set forth plans for the use of stem cells and regenerative medicine for a variety of neurological disorders, including Parkinson's Disease, stroke and brain cancer. Dr. Steindler currently is the Joseph J. Bagnor/Shands Professor of Medical Research in the Department of Neurological Surgery of the University of Florida College of Medicine. He serves on the grants-review team of the California Institute for Regenerative Medicine (CIRM). He also serves on the scientific advisory board for the Michael J. Fox Foundation for Parkinson's Research, and acts as an advisor to the Accelerate Brain Cancer Cure Foundation.